US Patent

US8978647 — Nasal delivery

Formulation · Assigned to Optinose AS · Expires 2030-12-06 · 5y remaining

Vulnerability score 31/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a nasal delivery device and method for delivering a substance, such as a medication, into a subject's nasal cavity.

USPTO Abstract

A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nosepiece for fitting to a nostril of a subject, wherein the nosepiece comprises a tip element which includes a delivery aperture from which substance is in use delivered into the nasal cavity, and the tip element is at least in part tapered such as to be inclined to a longitudinal axis of the nosepiece, with the delivery aperture extending both laterally across the tip element and along a longitudinal extent of the tip element; a nozzle through which substance is in use delivered, preferably substantially axially to a longitudinal axis of the nosepiece, to the respective nasal cavity; and a delivery unit for delivering substance through the nozzle of the nosepiece.

Drugs covered by this patent

Patent Metadata

Patent number
US8978647
Jurisdiction
US
Classification
Formulation
Expires
2030-12-06
Drug substance claim
No
Drug product claim
Yes
Assignee
Optinose AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.